Analyzing Brainsway (NASDAQ:BWAY) and Minerva Surgical (NASDAQ:UTRS)

Brainsway (NASDAQ:BWAYGet Free Report) and Minerva Surgical (NASDAQ:UTRSGet Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, profitability, valuation, dividends and risk.

Analyst Recommendations

This is a summary of current ratings and target prices for Brainsway and Minerva Surgical, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Brainsway 0 0 2 0 3.00
Minerva Surgical 0 0 0 0 0.00

Brainsway currently has a consensus target price of $14.25, suggesting a potential upside of 29.66%. Given Brainsway’s stronger consensus rating and higher possible upside, research analysts clearly believe Brainsway is more favorable than Minerva Surgical.

Insider and Institutional Ownership

30.1% of Brainsway shares are held by institutional investors. 19.0% of Brainsway shares are held by insiders. Comparatively, 8.5% of Minerva Surgical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Brainsway and Minerva Surgical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Brainsway 9.01% 7.35% 4.72%
Minerva Surgical N/A N/A N/A

Risk and Volatility

Brainsway has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Comparatively, Minerva Surgical has a beta of 3.67, suggesting that its share price is 267% more volatile than the S&P 500.

Earnings & Valuation

This table compares Brainsway and Minerva Surgical”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Brainsway $43.46 million 4.78 $2.92 million $0.20 54.95
Minerva Surgical $51.69 million 0.00 -$34.11 million N/A N/A

Brainsway has higher earnings, but lower revenue than Minerva Surgical.

Summary

Brainsway beats Minerva Surgical on 9 of the 11 factors compared between the two stocks.

About Brainsway

(Get Free Report)

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

About Minerva Surgical

(Get Free Report)

Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company provides Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.

Receive News & Ratings for Brainsway Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainsway and related companies with MarketBeat.com's FREE daily email newsletter.